<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:chebi fb="36" ids="39048">ADA</z:chebi> and the EASD recently published a consensus statement for the medical management of <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>The authors advocate initial treatment with <z:chebi fb="0" ids="6801">metformin</z:chebi> monotherapy and lifestyle modification, followed by addition of basal insulin or a <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> if glycaemic goals are not met (tier 1 recommendations) </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> other <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering therapies are relegated to a secondary (tier 2) status and only recommended for selected clinical settings </plain></SENT>
<SENT sid="3" pm="."><plain>In our view, this algorithm does not offer physicians and patients the appropriate selection of options to individualise and optimise care with a view to sustained control of blood <z:chebi fb="105" ids="17234">glucose</z:chebi> and reduction both of <z:mp ids='MP_0002055'>diabetes</z:mp> complications and cardiovascular risk </plain></SENT>
<SENT sid="4" pm="."><plain>This paper critically assesses the basis of the <z:chebi fb="36" ids="39048">ADA</z:chebi>/EASD algorithm and the resulting tiers of treatment options </plain></SENT>
</text></document>